Introduced quality risk management (ICH Q9)

ICH Q9 sets out a systematic approach to the assessment, control, communication and review of risks to the quality of a medicinal product across its lifecycle. Two principles sit at its centre: that the evaluation of risk should be based on scientific knowledge and ultimately linked to the protection of the patient, and that the level of effort, formality and documentation of the process should be commensurate with the level of risk. The guideline is deliberately tool-agnostic, describing recognised methods such as failure mode and effects analysis, fault tree analysis, hazard analysis and critical control points, and risk ranking and filtering, rather than mandating any single technique.

“Ergopharm applies quality risk management so that the rigour of assessment and documentation is proportionate to the risk a decision poses to product quality and, ultimately, to the patient.”

Ergopharm has integrated these principles into its existing quality system rather than treating them as a separate exercise. Risk assessments now inform how the company scopes qualification of equipment and utilities, prioritises deviation and out-of-specification investigations, frames change-control proposals, and designs the controls and monitoring around its sterile injectable lines. Where a proposed change or an observed deviation carries a higher potential impact on product quality, the associated assessment, review and documentation are correspondingly more rigorous; lower-risk matters are handled proportionately, so that attention and resource follow the risk to the patient.

This alignment is a matter of Ergopharm's own internal governance and process design. It is not a marketing approval and confers no national registration; rather, it reflects how the company has chosen to structure its Pharmaceutical Quality System so that decisions are traceable to a documented rationale. Assessments are recorded, periodically reviewed and revisited when new knowledge emerges, in keeping with the guideline's emphasis on risk communication and review as continuing activities rather than one-off judgements.

For Ergopharm, whose products are manufactured under GMP for export, a common risk-management vocabulary also supports consistent dialogue with contract partners, suppliers and importing-market stakeholders. By anchoring internal standard operating procedures to the ICH Q9 framework, the company aims to make its quality reasoning legible and repeatable across sites and functions, from incoming-material controls through to Qualified Person release.